PetrubAI

PerturbAI is an early-stage biotech firm leveraging a novel integration of in vivo CRISPR screening and AI to build causal maps of gene function and disease mechanisms. Founded in 2021, the company's core technology platform is designed to generate large-scale perturbation datasets from living organisms, which are used to train predictive biological models for therapeutic discovery. This approach seeks to de-risk and accelerate the identification of novel drug targets and mechanisms by moving beyond correlative data to establish causal relationships. As a private, pre-revenue platform company, PerturbAI is positioned at the intersection of functional genomics and machine learning, a high-potential but competitive space.

Integrated platform combining scalable in vivo CRISPR perturbation in living organisms with AI/ML. Generates organism-scale perturbation atlases linking genes to cells, circuits, and disease phenotypes to train predictive biological models for therapeutic discovery.

PerturbAI competes in the broad AI/ML drug discovery space against companies like Recursion, Exscientia, and Insilico Medicine, but its emphasis on large-scale in vivo perturbation is a key differentiator from many peers relying on in vitro or public data. It also faces competition from large biopharma internal efforts and academic consortia building perturbation maps, though with a less integrated discovery-to-drug focus.